Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance).
Kristie A BlumMei-Yin PolleySin-Ho JungTravis J DockterSarah AndersonEric D HsiNina Wagner-JohnstonBeth ChristianJim AtkinsBruce D ChesonJohn P LeonardNancy L BartlettPublished in: Cancer (2019)
The CR rates, PFS, and OS were not improved with the addition of bortezomib to ofatumumab and bendamustine in patients with high-risk FL. Although grade 3 to 4 toxicities were similar, more patients treated with bortezomib required dose modifications and early discontinuation.